Overall Technical outlook

Price Summary

2026-04-30, saw GLENMARK's stock open at 2400.1, hit a peak of 2455.9, fall to a low of 2385.6, and close up 0.26% at 2406.3, with 792783 shares changing hands.
During the 52-week span, the stock hit a high of 2413.9 and a low of 0.0.
The price outlook for GLENMARK is between 1500.0 and 2735.0, with an average expectation of 2227.3635, as estimated by 11 analysts.

Technicals


Aroon: The AROON is in a neutral stance, with no clear direction indicated for the market. This lack of clarity suggests that the market may be in a state of equilibrium for GLENMARK, with no strong trend emerging.
GLENMARK aroon 9b2d4d
Aroon chart for Glenmark Pharmaceuticals Limited


Bol. Bands: The current state of the BOLL BANDS is neutral, providing no clear signals for either an upward or downward movement. This indicates that the market may be in a state of equilibrium, with no strong momentum in either direction.
GLENMARK bbands 9b2d4d
Bolinger Bands chart for Glenmark Pharmaceuticals Limited


Parabolic SAR: The PSAR continues its bullish outlook, establishing a support level that could help sustain the current upward trend. This level of support may act as a cushion against potential downturns, indicating continued strength in the market's bullish momentum for GLENMARK.
GLENMARK psar 9b2d4d
Parabolic Stop and Reverse chart for Glenmark Pharmaceuticals Limited


Stochastic: The K-line for GLENMARK has dipped below the D-line on the stochastic indicator, while remaining above 80, suggesting that a bearish price move might be beginning. This pattern could indicate that the market's upward momentum is fading, possibly leading to a decline. Investors should keep an eye on this potential reversal.
GLENMARK stoch 9b2d4d
Stochastic chart for Glenmark Pharmaceuticals Limited


Tripple Moving Agerage: The 20, 50, and 100 moving averages are currently aligned in a bearish pattern, indicating a downtrend. However, the slopes of the 20 and 50 SMAs are showing signs of wavering, suggesting that the bearish momentum for GLENMARK may be fading. This could signal a potential shift towards bullish price action, as the market's downward trajectory begins to lose strength and prepares for a possible reversal.
GLENMARK trippleSMA 9b2d4d
Tripple SMA chart for Glenmark Pharmaceuticals Limited


When analyzing a company, its fundamentals—such as earnings, management efficiency, and strategic initiatives—must be considered alongside technical data. The context of the industry in which the company operates also plays a key role, as market trends and competitive dynamics can significantly impact performance. By taking a comprehensive approach, combining both fundamental and technical analysis, one can gain a deeper understanding of the company's potential for growth or risk.